Identification of immune-associated biomarker for predicting lung adenocarcinoma: bioinformatics analysis and experiment verification of PTK6
View abstract on PubMed
Summary
This summary is machine-generated.Protein tyrosine kinase 6 (PTK6) is a prognostic biomarker in lung adenocarcinoma (LUAD), correlating with immune infiltration and PD-L1 expression. Inhibiting PTK6 reduces LUAD cell proliferation and migration while inducing apoptosis.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Abnormal protein tyrosine kinase 6 (PTK6) expression is implicated in gynecological tumors.
- The immune-related carcinogenic role of PTK6 in other cancers is not well understood.
Purpose Of The Study
- To identify PTK6 as a prognostic biomarker in pan-cancer, particularly in lung adenocarcinoma (LUAD).
- To investigate the correlation between PTK6 expression, clinicopathological features, and immune infiltration in LUAD.
Main Methods
- Bioinformatic analysis of prognostic value and immune relevance of PTK6.
- In vitro validation using LUAD cell lines (PC9, NCI-H1975, HCC827) and normal lung cells (BEAS-2B).
- Western blot, CCK-8 assay, colony formation, wound healing, trans-well, flow cytometry, and analysis of immune checkpoints (PD-L1).
Main Results
- PTK6 is an independent predictive factor for LUAD with significant correlation to pathological stage and poor survival.
- KEGG and GSEA analysis revealed enrichment in cell cycle and TGF-β signaling pathways.
- PTK6 expression is associated with immune infiltration; PTK6 inhibition reduced proliferation and migration, induced apoptosis, and upregulated PD-L1.
Conclusions
- PTK6 serves as a predictive biomarker for LUAD prognosis.
- PTK6 expression influences immune infiltration and PD-L1 levels in LUAD.

